Sanofi Blood Cancer Drug Nixed on Safety Concerns

Washington Drug Letter
A A
Sanofi has decided to stop pursuing regulatory filing for its blood cancer drug fedratinib after new safety concerns arose from several clinical trials.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00